Bank of New York Mellon
CMPI

Bank of New York Mellon’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Bank of New York Mellon’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,188
Closed -$208K – 4512
2021
Q1 		$208K Sell
17,188
-248
-1% -$3.53K ﹤0.01% 4046
2020
Q4 		$254K Buy
+17,436
New +$222K ﹤0.01% 3890

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's CMPI Position: Q2 2021 in Review

Bank of New York Mellon sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2021, closing a stake of 17,188 shares — an estimated $208K sold.

Bank of New York Mellon first reported a position in CMPI in Q4 2020 and held it in 2 quarters. The position peaked at $254K in Q4 2020. 34 funds tracked by Wall St. Rank hold CMPI as of Q2 2021.

  • Bank of New York Mellon reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 17,188 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $208K.
  • Bank of New York Mellon first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Bank of New York Mellon's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $254K in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.